Argenx stock (NL0010832176): FDA expands Vyvgart approval to all gMG patients

Argenx SE announced a significant regulatory milestone on May 8, 2026, when the U.S. Food and Drug Administration approved label expansions for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), according to Ad-hoc-news as of May 8, 2026. The approval makes these therapies the first and only treatments approved for all adult patients with generalized myasthenia gravis (gMG), including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative cases.

As of: May 12, 2026

By the editorial team – specialized in equity coverage.

Argenx SE: core business model

Argenx is a global immunology company focused on developing antibody-based therapies for severe autoimmune diseases. The Dutch biopharmaceutical company, listed on Nasdaq, specializes in FcRn inhibition technology, which targets a key mechanism in autoimmune conditions. Vyvgart represents the company's lead therapeutic asset, addressing a significant unmet medical need in generalized myasthenia gravis, a chronic neuromuscular disease characterized by fluctuating weakness in skeletal and respiratory muscles.

Main revenue and product drivers for Argenx

Vyvgart and Vyvgart Hytrulo are Argenx's primary commercial drivers. The May 8 FDA approval expands the addressable patient population by removing serotype restrictions, allowing treatment of all adult gMG patients regardless of antibody status. This regulatory decision broadens market access in the United States, a key revenue market for the Nasdaq-listed biotech, according to Benzinga as of May 12, 2026. The approval follows positive clinical data demonstrating efficacy across all serotypes, strengthening the company's competitive position in the gMG treatment landscape.

Stock performance and market context

Argenx shares were trading at $800.41 on May 12, 2026, up 2.33% on the day following the FDA approval announcement. Over the past month, the stock has gained approximately 0.3%, underperforming the S&P 500's 9.3% gain during the same period. Year-to-date, Argenx is down roughly 5% compared to the index's 7.9% gain, reflecting broader biotech sector volatility.

Conclusion

The FDA's label expansion for Vyvgart and Vyvgart Hytrulo represents a meaningful regulatory achievement for Argenx, removing serotype restrictions and positioning these therapies as treatment options for all adult gMG patients in the United States. The approval broadens the addressable patient population and underscores the company's leadership in FcRn inhibition technology. Investors should monitor clinical adoption rates and revenue contribution from the expanded indication in upcoming quarterly results.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.